Peng Lu Sells 15,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Key Points

• Peng Lu sold 15,000 shares on April 30 at an average of $30.24 for $453,600 and, along with earlier April sales (7,001; 3,733; 100), sold a total of 25,834 shares in April, cutting his stake by 18.5% to 66,083 shares (≈ $1.998M).
• PHVS stock traded down 5.1% to $29.44 on heavy volume (512,191 shares vs. avg. 245,049), trading near its 12‑month high of $31.14 with 50‑ and 200‑day moving averages of $27.62 and $26.03.
• Pharvaris reported Q1 EPS of ($0.84), missing consensus (−$0.69), and analysts hold a mixed but overall "Moderate Buy" view with an average price target of $42.73.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Peng Lu sold 15,000 shares of Pharvaris stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total value of $453,600.00. Following the completion of the transaction, the insider owned 66,083 shares of the company's stock, valued at approximately $1,998,349.92. The trade was a 18.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Peng Lu also recently made the following trade(s):

• On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The shares were sold at an average price of $30.06, for a total value of $112,213.98.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,380.05.

Pharvaris Trading Down 5.1%

PHVS traded down $1.57 during trading on Friday, hitting $29.44. The company's stock had a trading volume of 512,191 shares, compared to its average volume of 245,049. The firm's 50 day moving average price is $27.62 and its two-hundred day moving average price is $26.03. Pharvaris N.V. has a 12 month low of $14.59 and a 12 month high of $31.14.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Analysts predict that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PHVS has been the subject of several research analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research report on Tuesday, April 21st. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research note on Monday, April 6th. Wedbush lifted their target price on Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a research note on Tuesday, April 7th. Citigroup reissued a "buy" rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $42.73.

Institutional Investors Weigh In On Pharvaris

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL acquired a new stake in shares of Pharvaris in the 3rd quarter valued at $1,943,000. Patient Square Capital LP increased its stake in shares of Pharvaris by 41.4% in the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company's stock valued at $8,617,000 after buying an additional 101,098 shares during the period. Boothbay Fund Management LLC increased its stake in shares of Pharvaris by 735.1% in the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company's stock valued at $3,373,000 after buying an additional 118,994 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 710.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company's stock valued at $676,000 after buying an additional 23,743 shares during the period. Finally, General Atlantic L.P. increased its stake in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock valued at $200,380,000 after buying an additional 500,000 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.